Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ferring Pharmaceuticals

< Previous 1 2 Next >
News headline image
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
From Ferring Pharmaceuticals
Via Business Wire
News headline image
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities
From Ferring Pharmaceuticals
Via Business Wire
News headline image
More Real-World Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at IDWeek 2023
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
From Ferring Pharmaceuticals
Via Business Wire
News headline image
First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Tickers RPRX
News headline image
Largest Integrated Safety Analysis From Five Prospective Clinical Trials for REBYOTA® (fecal microbiota, live – jslm) Published in Therapeutic Advances in Gastroenterology
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals Receives U.S. FDA Approval of Drug Substance Manufacturing Scale-up Process for Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring to Present Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals Announces Availability of REBYOTA™ (fecal microbiota, live – jslm) – the First and Only FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrence of C. diff Infection in Adults
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic
From Ferring Pharmaceuticals
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.